Drug Trial Radar · NCT04938830
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,003
Actual
Start
Nov 30, 2021
Primary completion
Apr 28, 2025
Study completion Aug 1, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
Conditions
- RSV Infection
Interventions
ClesrovimabBiological
IM injection
PalivizumabBiological
IM injection
PlaceboBiological
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Solicited Injection-site Adverse Events (AEs) in RSV Season 1Time frame: Up to 5 days after each dose in RSV Season 1 (Up to ~33 days)
- Number of Participants With Solicited Daily Body Temperatures With Fever in RSV Season 1Time frame: Up to 5 days after each dose in RSV Season 1 (Up to ~33 days)
- Number of Participants With Solicited Systemic AEs in RSV Season 1Time frame: Up to 5 days after each dose in RSV Season 1 (Up to ~33 days)
- Number of Participants With Anaphylaxis/Hypersensitivity AEs of Special Interest (AESI) in RSV Season 1Time frame: Up to 42 days in RSV Season 1
- Number of Participants With Rash AESI in RSV Season 1Time frame: Up to 42 days in RSV Season 1
- Number of Participants With Nonserious AEs in RSV Season 1Time frame: Up to 42 days in RSV Season 1
- Number of Participants With Serious AEs (SAEs) Through the Duration of Participation in RSV Season 1Time frame: Up to 365 days in RSV Season 1
Locations
146 sites in 27 countries. Site status is shown where the registry gives one.
Miller Children's & Women's Hospital Long Beach ( Site 0001)
Long Beach, California
Children's Hospital of Orange County ( Site 0047)
Orange, California
Children's Hospital Colorado ( Site 0011)
Aurora, Colorado
Children's National Medical Center ( Site 0020)
Washington D.C., District of Columbia
Orlando Health - Arnold Palmer Hospital-Orlando Health-Arnold Palmer Hospital Pulmonary and Sleep M ( Site 0022)
Orlando, Florida
Nemours Children's Health, Lake Nona Medical City ( Site 0032)
Orlando, Florida
University of South Florida-Department of Pediatrics ( Site 0045)
Tampa, Florida
Morehouse School Of Medicine ( Site 0049)
Atlanta, Georgia
Clinical Research Prime ( Site 0046)
Idaho Falls, Idaho
University of Kentucky HealthCare - Turfland ( Site 0044)
Lexington, Kentucky
Our Lady of the Lake Children's Hospital ( Site 0031)
Baton Rouge, Louisiana
Tulane University School of Medicine ( Site 0010)
New Orleans, Louisiana
M Health Fairview University of Minnesota Masonic Children's Hospital, West Bank-Peds Research ( Site 0037)
Minneapolis, Minnesota
Rutgers University-Pediatric Clinical Research Center ( Site 0007)
New Brunswick, New Jersey
NYU Langone Hospital - Long Island-Pediatrics ( Site 0028)
Mineola, New York
University of Rochester Medical Center ( Site 0017)
Rochester, New York
The University of North Carolina at Chapel Hill ( Site 0035)
Chapel Hill, North Carolina
Duke University ( Site 0021)
Durham, North Carolina
Dayton Children's Hospital ( Site 0053)
Dayton, Ohio
Tribe Clinical Research, LLC ( Site 0002)
Greenville, South Carolina
Driscoll Children's Hospital ( Site 0025)
Corpus Christi, Texas
DHR Health Institute for Research and Development ( Site 0029)
Edinburg, Texas
Christus Children's-Clinical Research Center ( Site 0038)
San Antonio, Texas
University Hospital-Pediatrics ( Site 0019)
San Antonio, Texas
Road Runner Research, Ltd ( Site 0052)
San Antonio, Texas
Intermountain - Primary Children's Hospital ( Site 0026)
Salt Lake City, Utah
Multicare Rockwood Main Clinic-Rockwood Pediatrics ( Site 0004)
Spokane, Washington
Providence Sacred Heart Medical Center & Children's Hospital ( Site 0030)
Spokane, Washington
MultiCare Health System-Baker Center ( Site 0036)
Tacoma, Washington
Mater Misericordiae Limited-Neonatalogy ( Site 0102)
Brisbane, Queensland, Australia
Telethon Kids Institute-Vaccine Trials Group ( Site 0101)
Nedlands, Western Australia, Australia
Alberta Children's Hospital-Department of Pediatrics ( Site 0180)
Calgary, Alberta, Canada
Canadian Center for Vaccinology ( Site 0179)
Halifax, Nova Scotia, Canada
CHU Sainte-Justine ( Site 0178)
Montreal, Quebec, Canada
Clínica Alemana de Santiago-Neonatology department ( Site 0207)
Santiago, Region M. de Santiago, Chile
Hospital Roberto del Río-Infectología Pediátrica ( Site 0205)
Santiago, Region M. de Santiago, Chile
Hospital Padre Hurtado-NEONATOLOGY/PEDIATRICS ( Site 0201)
Santiago, Region M. de Santiago, Chile
Fundación Hospitalaria San Vicente de Paúl ( Site 0233)
Medellín, Antioquia, Colombia
Clínica Universitaria Bolivariana ( Site 0227)
Medellín, Antioquia, Colombia
Ciensalud Ips S A S ( Site 0235)
Barranquilla, Atlántico, Colombia
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.